Montelukast Sodium Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

The Montelukast Sodium Market is segmented by Dosage Form, Application, and Geography

Market Snapshot

CAGR
Study Period: 2018 - 2026
Base Year: 2020
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: 12.6 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The montelukast sodium market studied was projected to record a CAGR of nearly 12.6% over the forecast period. The major factor attributing to the growth of the market is the increase in the prevalence of diseases, such as asthma, exercise-induced bronchospasm, allergic rhinitis, primary dysmenorrhea, and urticaria.

According to the World Health Organization, around 235 million people are living with asthma. Over 80% of asthma-related deaths occur in low-and lower-middle-income countries. As the number of patients increases, the demand for montelukast sodium also rises. However, side effects with the product, such as stomach pain, heartburn, upset stomach, nausea, and diarrhea, restrain the market growth.

Scope of the Report

As per the scope of the report, montelukast sodium is a leukotriene inhibitory agent that is used for many indications, including asthma, exercise-induced bronchospasm, allergic rhinitis, primary dysmenorrhea, and urticaria. It is used to prevent shortness of breath and breathing problems.

By Dosage Form
Tablets
Oral Solutions
By Application
Asthma
Allergic Rhinitis
Urticaria
Other Applications
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Rest of the World

Report scope can be customized per your requirements. Click here.

Key Market Trends

Asthma Segment is Found Dominating the Montelukast Sodium Market

Montelukast sodium is used to prevent wheezing, difficulty breathing, chest tightness, and coughing caused by asthma in adults and children 12 months of age and older. With the growing prevalence of asthma globally, the usage of montelukast sodium also increases. According to the Centers for Disease Control and Prevention (CDC), 1 in 13 people have asthma. More than 25 million Americans have asthma, i.e. 7.7% of adults and 8.4% of children in 2017. There are about 6.2 million children under the age of 18 with asthma. Asthma accounts for 9.8 million doctor’s office visits, 188,968 discharges from hospital inpatient care and 1.8 million emergency department visits each year. Hence, with the rising incidence and prevalence of asthma, it is expected to increase the demand for montelukast sodium resulting in the high growth of the market.

Prevalence of Asthma(per 100,000), by Country, 2017

North America is Dominating the Montelukast Sodium Market

North America is expected to dominate the overall market, due to factors, such as the presence of key players, high prevalence of asthma and other respiratory diseases, established healthcare infrastructure, which are some of the key factors accountable for its large share in the market. Furthermore, beneficial government initiatives and an increase in the number of research partnerships are some of the drivers expected to increase the market growth.

In this region, the United States has the maximum share due to supportive healthcare policies, a high number of patients, and a developed healthcare market. According to the Centers for Disease Control, in 2017, around 8.1% of the population of the United States currently had asthma. As per the statistics, the increasing patient pool and increasing disposable revenue in this country boost the market growth of the region.

Montelukast Sodium market

Competitive Landscape

The montelukast sodium market is moderately competitive and consists of several major players. Some of the companies that are currently dominating the market are Merck & Co. Inc., Morepen Laboratories, Teva Pharmaceuticals USA Inc., Mylan NV, Cipla Limited, Intas Pharmaceuticals Ltd, SUN PHARMA, Apotex Inc, Sanyo Chemical Industries Ltd, and Delmar Chemicals Inc.

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Increasing Prevalence of Disease like Asthma, Allergic Rhinitis, etc.

      2. 4.2.2 Rise in Geriatric Population

    3. 4.3 Market Restraints

      1. 4.3.1 Side Effects of the Product

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Dosage Form

      1. 5.1.1 Tablets

      2. 5.1.2 Oral Solutions

    2. 5.2 By Application

      1. 5.2.1 Asthma

      2. 5.2.2 Allergic Rhinitis

      3. 5.2.3 Urticaria

      4. 5.2.4 Other Applications

    3. 5.3 Geography

      1. 5.3.1 North America

        1. 5.3.1.1 United States

        2. 5.3.1.2 Canada

        3. 5.3.1.3 Mexico

      2. 5.3.2 Europe

        1. 5.3.2.1 Germany

        2. 5.3.2.2 United Kingdom

        3. 5.3.2.3 France

        4. 5.3.2.4 Italy

        5. 5.3.2.5 Spain

        6. 5.3.2.6 Rest of Europe

      3. 5.3.3 Asia-Pacific

        1. 5.3.3.1 China

        2. 5.3.3.2 Japan

        3. 5.3.3.3 India

        4. 5.3.3.4 Australia

        5. 5.3.3.5 South Korea

        6. 5.3.3.6 Rest of Asia-Pacific

      4. 5.3.4 Rest of the World

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 Merck & Co. Inc.

      2. 6.1.2 Morepen Laboratories

      3. 6.1.3 Teva Pharmaceuticals USA Inc.

      4. 6.1.4 Mylan NV

      5. 6.1.5 Cipla Limited

      6. 6.1.6 Intas Pharmaceuticals Ltd

      7. 6.1.7 SUN PHARMA

      8. 6.1.8 Apotex Inc

      9. 6.1.9 Sanyo Chemical Industries Ltd

      10. 6.1.10 Delmar Chemicals Inc.

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape Covers- Business Overview, Financials, Products and Strategies and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Montelukast Sodium Market market is studied from 2018 - 2026.

The Montelukast Sodium Market is growing at a CAGR of 12.6% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2020.

Merck & Co., Inc., Morepen Laboratories, Teva Pharmaceuticals USA, Inc., Mylan N.V., Cipla Limited are the major companies operating in Montelukast Sodium Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!